Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease

Chen-Ming Sun, Jie Wu, Heng Zhang, Gan Shi, Zhi-Tao Chen

AIM
To determine the association of circulating miR-125a/b expression with the risk and disease severity of Crohn's disease (CD), and with inflammatory cytokines.

METHODS
Plasma samples were collected from patients with active CD (A-CD), or CD in remission (R-CD) and from healthy controls (HCs). The levels of the inflammatory cytokines interleukin-17 (IL-17), tumour necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) were measured by enzyme-linked immunosorbent assay. The expression of miR-125a/b was assessed by quantitative polymerase chain reaction (qPCR).

RESULTS
Twenty-nine A-CD patients, 37 R-CD patients, and 37 HCs were included in the study. Plasma miR-125a expression was decreased in A-CD patients compared
with that in R-CD patients ($P < 0.001$) and HCs ($P < 0.001$). miR-125a expression levels enabled the differentiation of A-CD from R-CD patients [area under curve (AUC) = 0.854] and from HCs (AUC = 0.780), whereas miR-125b expression did not. miR-125a was negatively correlated with C-reaction protein (CRP) ($P = 0.017$), erythrocyte sedimentation rate (ESR) ($P = 0.026$), Crohn’s disease activity index (CDAI) ($P = 0.003$), IL-17 ($P = 0.015$), and TNF-α ($P = 0.004$) in A-CD patients. Furthermore, miR-125a was negatively associated with CRP ($P = 0.038$) and CDAI ($P = 0.021$) in R-CD patients. Regarding miR-125b, no association with CRP, CDAI, IL-17, TNF-α, or IFN-γ was found in A-CD or in R-CD patients. miR-125a levels gradually increased in A-CD patients who achieved clinical remission ($P = 0.009$) after 3-mo treatment, whereas they remained unchanged among patients who failed to achieve remission. No changes in miR-125b expression were detected in remission or non-remission patients after treatment.

**CONCLUSION**
Circulating miR-125a but not miR-125b is decreased in patients with active disease status and negatively correlates with disease severity and inflammatory cytokines in patients with CD.

**Key words:** Crohn’s disease; miR-125; Disease risk; Disease severity; Inflammatory cytokines

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This study aimed to investigate the association of circulating miR-125a/b expression with the risk and severity of Crohn’s disease (CD) and with inflammatory cytokines. Our results showed that miR-125a but not miR-125b is negatively correlated with the risk of active CD and disease severity and with inflammatory cytokines.

INTRODUCTION
Crohn’s disease (CD), an idiopathic chronic inflammatory disease, is a form of inflammatory bowel disease (IBD) and primarily affects the gastrointestinal tract. This disease causes the development of ulcers and complications, including abscesses and fistulas, affecting all layers of the intestinal wall[1,2]. It is reported that CD has an annual incidence of approximately 24 per 100000 in Europe and 19 per 100000 in North America. However, the incidence rate of CD is still increasing in developing countries, particularly in China due to its considerable increase in gross domestic product (GDP) [3,4] and improvement in quality of life[5].

MicroRNAs (miRNAs) are small endogenous RNAs that can degrade targeted mRNA or inhibit protein synthesis, and increasing evidence shows that miRNAs play a key role in regulating the intestinal immune system [6-9]. For example, miR-29b inhibits transforming growth factor-β (TGF-β)-induced intestinal fibrosis, and let-7 regulates the activity of nuclear factor-xB (NF-κB) and mediates interleukin (IL)-6 down-regulation in CD patients [10,11]. Furthermore, miR-192, miR-142-3p, and miR-21 are notably upregulated in paediatric IBD patients [12], whereas miR-495-5p and miR-19b are down-regulated in the inflamed bowel of CD patients [13,14].

miRNA-125 (miR-125) family, an mRNA family highly conserved throughout evolution, consists of miR-125a and miR-125b [15]. It has been shown that miR-125a inhibits innate macrophage responses by suppressing macrophage differentiation, and the expression level of miR-125a is down-regulated in systemic lupus erythematosus (SLE) [16,17]. miR-125b was correlated with rheumatoid arthritis (RA) disease activity and may serve as a potential biomarker for treatment response in early RA [18]. To date, few studies have investigated the impact of dysregulated miR-125a/b expression in CD patients. Therefore, the aim of this study was to determine the association of circulating miR-125a/b expression with the risk and disease severity of CD and with inflammatory cytokines.

**MATERIALS AND METHODS**

**Participants**
Twenty-nine clinically active CD (A-CD) patients and 37 patients with CD in clinical remission (R-CD) were enrolled in this study from May 2014 to June 2016 at the Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology. The diagnosis of CD was determined according to the Lennard-Jones criteria [19], and active clinical disease was defined as Crohn’s disease activity index (CDAI) above 150 points. Patients with the following conditions were excluded: arthritis with complications or other autoimmune diseases; history of malignant tumour or complications; severe renal and/or kidney dysfunction; and history of serious surgery or severe infection. In the meantime, 37 healthy controls (HCs) age- and gender-matched to the CD patients were enrolled.

The study was approved by the Ethics Committee of The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, and
all participants provided written informed consent.

Sample collection and total RNA extraction

Blood samples were collected from all participants into EDTA tubes when they were enrolled in this study and after a 3-mo treatment in the case of A-CD patients. After collection, the blood samples were centrifuged at 1000 \( g \) for 15 mins at 4 \(^{\circ}\)C; then, the supernatant (plasma) was removed and stored at -80 \(^{\circ}\)C for further analysis. If red blood cell lysis was discovered, a repeat blood sample was collected from patients or HCs. Total RNA was extracted from the samples with TRIzol reagent (Invitrogen, CA, United States) according to the manufacturer's instructions.

miR-125a/b determination by qPCR

Total RNA was reverse transcribed using the PrimerScript Real-time Reagent kit (TAKARA BIO Inc. Shiga, Japan). Subsequently, miR-125 a/b expression levels were quantitated with SYBR Premix Ex TaqTM II (TAKARA BIO Inc., Shiga, Japan). The expression level of miR-125a/b was calculated using the 2^{-ΔΔt} method and U6 was used as the internal reference.

IL-17, TNF-\( \alpha \), and IFN-\( \gamma \) measurement by ELISA

The measurement of IL-17, tumour necrosis factor (TNF-\( \alpha \)), and interferon (IFN-\( \gamma \)) levels in plasma samples from A-CD and R-CD patients (but not HCs) was performed using commercial enzyme-linked immunosorbent assay (ELISA) kits, according to the manufacturer's instructions (all purchased from eBioscience, CA, United States).

Disease evaluation and treatment of A-CD patients

C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and Crohn's disease activity index (CDAI) were used to assess the severity of CD. In A-CD patients, effective treatments, including immunosuppressive agents and biologics, among others, were used, according to disease status and clinical experience. After 3-mo treatment, the CDAI and blood of patients were assessed again, and changes in miR-125a/b expression were analysed based on clinical remission achievement.

### Table 1 Demographic and clinical characteristics of active Crohn’s disease patients, patients with Crohn’s disease in remission, and healthy controls

| Parameter      | A-CD patients (n = 29) | R-CD patients (n = 37) | HCs (n = 37) | P      |
|----------------|------------------------|------------------------|--------------|--------|
| Age (yr)       | 31.38 ± 9.51           | 31.97 ± 8.86           | 31.41 ± 5.69 | 0.941* |
| Gender (female/male) | 17/12                  | 20/17                  | 18/19        |        |
| CRP (mg/L)     | 45.96 (32.27-67.26)    | 18.94 (10.78-26.71)    | 3.99 (3.33-6.06) | < 0.001* |
| ESR (mm/1h)    | 43.93 (37.46-57.82)    | 16.73 (11.36-20.40)    | 13.02 (5.82-15.27) | < 0.001* |
| CDAI score     | 206.0 (170.5-253.0)    | 95.0 (75.5-112.0)      |              |        |
| IL-17 (pg/mL)  | 46.90 (38.46-60.06)    | 18.07 (10.21-20.17)    |              | < 0.001* |
| TNF-\( \alpha \) (pg/mL) | 72.77 (53.46-83.39) | 22.17 (19.49-30.43)   |              | < 0.001* |
| INF-\( \gamma \) (pg/mL) | 35.23 (24.59-39.54) | 11.62 (9.16-15.07)    |              | < 0.001* |

Data are presented as mean ± SD, median (1/4-3/4 quarters), or counts. *Comparison among three groups, determined by One-way analysis of variance (ANOVA), Kruskal-Wallis test by ranks, or \( \chi^2 \) test; †Comparison between A-CD and R-CD groups, determined by Wilcoxon signed-rank test. A-CD: Active Crohn’s disease; R-CD: Crohn’s disease in remission; HCs: Healthy controls; CRP: C reactive protein; ESR: Erythrocyte sedimentation rate; CDAI: Crohn’s disease activity index.
Comparisons among three groups were performed by one-way analysis of variance (ANOVA), Kruskal-Wallis test by ranks, or $\chi^2$ test. Comparisons between groups or between each visit in the same group were performed using Statistical analyses were performed using SPSS 21.0 software program (IBM, United States) and MS Office 2016 (Microsoft, United States). Data are mainly expressed as mean ± standard deviation, median (1/4-3/4 quarters), or counts. Comparisons among three groups were performed by one-way analysis of variance (ANOVA), Kruskal-Wallis test by ranks, or $\chi^2$ test. Comparisons between groups or between each visit in the same group were performed using Statistical analysis

Statistical analyses were performed using SPSS 21.0 software program (IBM, United States) and MS Office 2016 (Microsoft, United States). Data are mainly expressed as mean ± standard deviation, median (1/4-3/4 quarters), or counts. Comparisons among three groups were performed by one-way analysis of variance (ANOVA), Kruskal-Wallis test by ranks, or $\chi^2$ test. Comparisons between groups or between each visit in the same group were performed using

Figure 2  Receiver operating characteristic curve analysis of miR-125a/b for prediction of active Crohn's disease patients and patients with Crohn's disease in remission. Receiver operating characteristic curve was operated to assess miR-125a/b expression in differentiating A-CD patients from R-CD patients and from HCs. miR-125a was able to differentiate A-CD patients from R-CD (A) patients and from HCs (B), whereas miR-125b was not (A, B). Neither miR-125a nor miR-125b could differentiate R-CD from HCs (C). A-CD: Active Crohn's disease; R-CD: Crohn's disease in remission; HCs: Healthy controls.

Figure 3  Correlations of miR-125a/b expression with disease severity in active Crohn's disease patients. A-C: Correlations of miR-125a expression with disease severity in A-CD patients; D-F: Correlations of miR-125b expression with disease severity in A-CD patients. Spearman's test was used to analyse the correlation of miR-125a/b expression with disease severity. $P < 0.05$ was considered significant. A-CD: Active Crohn's disease; R-CD: Crohn's disease in remission; HCs: Healthy controls.

Sun CM et al. Circulating miR-125a/b in CD
the Wilcoxon signed-rank test. Receiver operating characteristic (ROC) curve analysis was performed to assess the value of miR-125a/b expression in differentiating A-CD from R-CD patients and patients from HCs. Spearman’s test was used to analyse the correlation of miR-125a/b expression with disease severity and inflammatory cytokines. \( P < 0.05 \) was considered significant.

**RESULTS**

**Characteristics**

As shown in Table 1, the 29 patients of the A-CD group had a mean age of 31.38 ± 9.51 years, whereas the 37 patients of the R-CD and the 37 HCs had a mean ages of 31.97 ± 8.86 and 31.41 ± 5.69 years, respectively. No difference in age or gender was found between groups (\( P > 0.05 \)), although significant differences in CRP and ESR (\( P < 0.001 \)) were observed between groups. Significant differences in inflammatory cytokines IL-17, TNF-\( \alpha \), and IFN and in CDAI were also found between A-CD and R-CD patients (\( P < 0.001 \)).

**miR-125a/b expression in A-CD patients, R-CD patients, and HCs**

Plasma miR-125a expression was decreased in A-CD patients [0.719 (0.534-1.072)] compared with that of R-CD patients [1.564 (1.159-2.851), \( P < 0.001 \)] and HCs [1.781 (0.874-2.873), \( P < 0.001 \)]. However, no significant difference between R-CD patients and HCs (\( P = 0.297 \)) was found (Figure 1A). No difference in miR-125b expression was observed between A-CD [2.707 (2.168-3.531)] and R-CD patients [2.600 (2.154-3.064)] and between patients and HCs [2.393 (1.705-2.852)], as shown in Figure 1B. Interestingly, diagnostic value was discovered for miR-125a in differentiating A-CD from R-CD patients [area under ROC curve (AUC) = 0.854, 95%CI: 0.758-0.949] and patients from HCs (AUC = 0.780, 95%CI: 0.665-0.895) (Figure 2A and B). However, miR-125b failed as a predictive factor in differentiating A-CD from R-CD patients (AUC = 0.571, 95%CI: 0.423-0.718) and patients from HCs (AUC = 0.629, 95%CI: 0.492-0.766) (Figure 2A and B). Moreover, neither miR-125a nor miR-125b was able to differentiate R-CD patients from HCs (AUC = 0.537, 95%CI: 0.406-0.668; AUC = 0.590, 95%CI: 0.461-0.720, respectively) (Figure 2C).

**Correlations of miR-125a/b expression with disease severity in CD patients**

Negative correlations of miR-125a with CRP (\( r = -0.342, P = 0.038, n = 37 \)) and ESR (\( r = -0.140, P = 0.410, n = 37 \)) were found (Table 2). miR-125a was negatively correlated with CDAI in A-CD patients (\( r = -0.379, P = 0.021, n = 37 \)) (Figure 2C).

![Figure 1](image1.png)

![Figure 2](image2.png)

![Figure 3](image3.png)

Table 2: Correlations of miR-125a and miR-125b expression with disease severity in CD patients.

| Cytokine | miR-125a | miR-125b |
|----------|----------|----------|
| CRP      | \( r = -0.342, P = 0.038, n = 37 \) | \( r = 0.068, P = 0.691, n = 37 \) |
| ESR      | \( r = -0.140, P = 0.410, n = 37 \) | \( r = 0.326, P = 0.049, n = 37 \) |
| CDAI     | \( r = -0.379, P = 0.021, n = 37 \) | \( r = 0.126, P = 0.457, n = 37 \) |

Figure 4: Correlations of miR-125a/b expression with disease severity in patients with Crohn’s disease in remission. A-C: Correlations of miR-125a expression with disease severity in R-CD patients; D-F: Correlations of miR-125b expression with disease severity in R-CD patients. Spearman’s test was used to analyse the correlation of miR-125a/b expression with disease severity. \( P < 0.05 \) was considered significant. A-CD: Active Crohn’s disease; R-CD: Crohn’s disease in remission; HCs: Healthy controls.
miR-125a in active CD patients

Regarding R-CD patients, we observed no correlation of miR-125a or miR-125b with the inflammatory factors IL-17, TNF-α or IFN-γ, as shown in Figure 6A-F.

**miR-125a/b expression in A-CD patients after treatment**

After 3-mo treatment, 19 of 29 A-CD patients achieved clinical remission (CDAI < 150), whereas 10 patients failed to achieve clinical remission. In patients with clinical remission, the miR-125a levels dramatically increased compared with the baseline (P = 0.009); conversely, in non-remission patients, miR-125a levels remained unchanged compared with the baseline. No changes in miR-125b expression were detected, either in remission or non-remission patients after treatment (Figure 7).

**DISCUSSION**

CD, a chronic debilitating syndrome, affects all layers of the gastrointestinal tract, causes severe diarrhea, abdominal pain, weight loss, metabolic disorder, and malabsorption, and is a major health concern, leading to huge financial losses of up to $2.2 billion dollars per year in the United States alone. Although the pathogenesis of CD is still unclear, accumulating evidence shows that environmental factors, genetics,
autoimmunity, and dietary habits may contribute to its development and progression\cite{24,25}. As an important genetic factor, miRNA dysregulation is involved in the aetiopathogenic mechanism of several autoimmune diseases, including CD\cite{26}; however, the role of miR-125a/b expression in CD risk and management is largely unstudied\cite{27}.

In this prospective study, we observed three notable findings. First, miR-125a expression was decreased in A-CD patients compared with R-CD patients and HCs. The results also showed the ability of miR-125a expression levels to distinguish A-CD from R-CD patients and from HCs, which was not possible using miR-125b expression levels. Second, miR-125a was negatively correlated with disease severity in A-CD patients, and negative correlations of miR-125a with inflammatory cytokines were also found in A-CD patients. Third, miR-125a levels were dramatically increased in A-CD patients who achieved clinical remission after 3-mo treatment, whereas miR-125a levels remained unchanged in non-remission patients. No changes in miR-125b expression were detected in remission or non-remission A-CD patients after treatment.

The miR-125a gene is located on chromosome 19 and in a cluster with miR-99b and miR-7e\cite{28}. In the healthy population, the largest contributor of circulating miR-125a may be germinal center (GC) and hematopoietic stem cells (HSCs). Shaham et al suggest that miR-125a is enriched in HSCs (up to 23-fold more than in total bone marrow), particularly in long-term HSCs (up to 6-fold). Moreover, miR-125a is not restricted to the stem cell population, and its cluster members, miR-99b and let-7e, are preferentially expressed by centroblasts in the GC\cite{16}. Studies show that miR-125a is down-regulated in peripheral CD3 T cells and negatively correlated with RANTES (also known as CCL5 chemokine) expression by targeting the KLF13 gene in SLE patients\cite{27}. Interestingly, miR-125a expression is also decreased in oral lichen planus, which is a T-cell-mediated autoimmune disease of the oral mucosa\cite{29}. Furthermore, miR-125a is identified as a key regulator of CD4 T-cell differentiation that prevents autoimmunity pathogenesis by controlling the balance between tolerance and autoimmunity\cite{30}.

Recently, it was reported that miR-125a participates in immune thrombocytopenic purpura (ITP), by modulating Tregs and Th1\textsuperscript{7}\cite{31}, which play a key role in CD development and progression and are correlated with inflammatory cytokines.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure6.png}
\caption{Correlations of miR-125a/b expression with inflammatory cytokines in patients with Crohn’s disease in remission. A-C: Correlations of miR-125a expression with inflammatory cytokines in R-CD patients; D-F: Correlations of miR-125b expression with inflammatory cytokines in R-CD patients. Spearman’s test was used to analyse the correlation of miR-125a/b expression with inflammatory cytokines. \textit{P} < 0.05 was considered significant. A-CD: Active Crohn’s disease; R-CD: Crohn’s disease in remission; HCs: Healthy controls.}
\end{figure}
with CD disease activity\cite{32-34}. These studies indicate that miR-125a is an anti-inflammatory gene that plays a key role in regulating autoimmune diseases, which is consistent with our results showing that miR-125a expression is decreased in A-CD patients and may be used to differentiate A-CD from R-CD patients and from HCs. This might be due to the anti-inflammatory effect of miR-125a, because the levels of inflammatory cytokines were markedly increased in A-CD patients compared with those of R-CD patients and HCs, whereas the extent of inflammation in R-CD patients was similar to that of HCs. The results showing a negative correlation between miR-125a and the inflammatory cytokines IL-17 and TNF-α further confirmed this point of view.

In addition, we found a negative association of miR-125a with disease severity in A-CD patients. Partly in line with our results, Murata et al\cite{35} reported that miR-125a was negatively correlated with some indices of disease activity including CRP in RA, and reduced levels of miR-125a were associated with severe trauma through inflammatory cytokine IL-10 regulation, as shown in polytrauma patients\cite{36}, most likely, because of the powerful anti-inflammatory effect of miR-125a. Thus, miR-125a was able to predict the disease severity of CD. Furthermore, we found that the miR-125a levels were dramatically increased in A-CD patients who achieved clinical remission after 3-mo treatment, whereas they remained unchanged in patients who failed to achieve remission. The results proved once again that miR-125a is closely related to inflammation and might be a therapeutic target for CD in the future.

Figure 7 miR-125a/b expression in active Crohn’s disease patients after treatment. After 3-mo treatment, miR-125a expression was increased in A-CD patients who achieved clinical remission but remained stable in patients who failed to achieve remission. Conversely, no changes in miR-125b expression were observed in either remission or non-remission patients after 3-mo treatment. Comparison between visits in the same group was performed by the Wilcoxon signed-rank test. P < 0.05 was considered significant. A-CD: Active Crohn’s disease.
miR-125-b has been shown to target the 3’ untranslated region of the TNF-α gene to negatively regulate the inflammatory response. However, another study has shown that miR-125b could promote macrophage mediated inflammation by increasing the expression of co-stimulatory factor. These studies suggest that miR-125b has both anti- and pro-inflammatory effects. We found no correlation of miR-125b with inflammatory factors in A-CD patients, and miR-125b was not able to differentiate A-CD from R-CD patients and from HCs, most likely because miR-125b has both anti- and pro-inflammatory effects, which has been reported in previous studies. Thus, the role of miR-125b in regulating inflammation in CD remains unclear. Then, we analysed the target genes of miR-125a and miR-125b by Validated Target Module-MicroRNA-gene analysis using the software miRWalk 2.0,[41], which showed that miR-125a had 234 reported target genes, whereas miR-125b had 391 reported target genes, and that they shared 110 target genes. Conversely, most miR-125a and miR-125b target genes were different, which may explain the differences between miR-125a and miR-125b in CD.

To the best of our knowledge, this was the first study investigating the correlation between circulating miR-125a/b expression and the risk and disease severity of CD and with inflammatory cytokines. Notwithstanding, there were still some limitations in our study. First, we did not detect the expression of miR-125a/b in the intestinal tract, where miRNA dysregulation might be more frequent than in blood. However, it is difficult to obtain normal intestinal tract tissue from HCs and CD patients who remain remission. Second, the sample size of our study was relatively small, and a larger sample is needed for further studies. Third, IL-17, TNF-α, and IFN-γ expression was not detected in HCs in this study, which would help to further elucidate the role of miR-125a/b in inflammation, which we will investigate in future studies. Finally, the levels of Tregs and Th17 cells, which are essential for CD development and progression, were not determined in the present study. We will also assess these levels in future studies.

In summary, circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity and inflammatory cytokines in patients with Crohn’s disease. Therefore, this study sheds some light on the measurement of circulating miR-125a for the diagnosis and treatment of CD patients.

**Research frontiers**

Accumulating evidence shows that environmental factors, genetics, autoimmunity, and dietary habits may contribute to the development and progression of CD. As an important genetic factor, dysregulated miRNA has been involved in the aetiological mechanism of several autoimmune diseases, including CD; however, the role of miR-125a/b expression in CD risk and management is largely unstudied.

**Innovations and breakthroughs**

This was the first study that investigated the correlation between circulating miR-125a/b expression and the risk and disease severity of CD and inflammatory cytokines. The authors showed that miR-125a but not miR-125b is negatively associated with the risk for A-CD and disease severity with inflammatory cytokines.

**Applications**

miR-125a is negatively associated with the risk for A-CD patients and disease severity and with inflammatory cytokines. In the near future, miR-125a may be an important marker for the diagnosis and treatment of CD patients.

**Terminology**

Crohn’s disease activity index (CDAI) was used to differentiate A-CD from R-CD patients. Patients with a CDAI above 150 points were defined as A-CD patients, and those with a CDAI below 150 points were defined as R-CD patients.

**Peer-review**

This work focused on two miRNA molecules and their potential relevance to IBD. It is a well-written and interesting manuscript.

**REFERENCES**

1. Smids C, Horjus Talabur Horje CS, Nierkens S, Drylewicz J, Groenen MIM, Wahab PJ, van Lochem EG. Candidate Serum Markers in Early Crohn’s Disease: Predictors of Disease Course. J Crohns Colitis 2017; 11: 1090-1100 [PMID: 28369318 DOI: 10.1093/jcc/jjx049]

2. Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn’s Disease: A Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis 2017; 11: 811-819 [PMID: 28333187 DOI: 10.1093/jcc/jjx005]

3. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, Wong TC, Leung VK, Tsang SW, Yu IH, Li MF, Ng KK, Kamn MA, Studd C, Bell S, Leong R, de Silva HJ, Kasturiratne A, Mufeena MN, Ling KL, Ooi CJ, Tan PS, Ong D, Goh KL, Hilmi I, Pisespongsa P, Manatsathit S, Rerknimit R, Aniwon S, Wang YF, Ouyang Q, Zeng Z, Zhu Z, Chen MH, Hu PJ, Wu K, Wang X, Simadibrata M, Abdullah M, Wu JC, Sung JJ, Chan FK. Asia-Pacific Crohn’s and Colitis Epidemiologic Study (ACCESS) Study Group. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013; 145: 158-165.e2 [PMID: 23583432 DOI: 10.1053/j.gastro.2013.04.007]

4. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dis 2010; 11: 76-82 [PMID: 20402832 DOI: 10.1111/j.1751-2980.2010.00421.x]

5. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e2, quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]

6. Pua HH, Ansel KM. MicroRNA regulation of allergic inflammation and asthma. Curr Opin Immunol 2015; 36: 101-108

**COMMENTS**

**Background**

Crohn’s disease (CD), an idiopathic chronic inflammatory disease, is a form of inflammatory bowel diseases (IBD) and primarily affects the gastrointestinal tract. Few studies have investigated the impact of dysregulated miR-125a/b expression in CD patients.

**Sun CM et al.** Circulating miR-125a/b in CD

"..."
Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6 [PMID: 23321005 DOI: 10.1186/1756-8722-6-6]

Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26: 2011-2018 [PMID: 22456625 DOI: 10.1038/leu.2012.90]

Dweep H, Sticht C, Pandey P, Gretz N. miRWalk—database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011; 44: 839-847 [PMID: 21605702 DOI: 10.1016/j.jbi.2011.05.002]

P- Reviewer: Day AS, Yeligar SM  S- Editor: Gong ZM  L- Editor: Wang TQ  E- Editor: Ma YJ
